Skip to content

EvolveImmune Therapeutics Welcomes Ian Taylor, PhD to the Board of Directors

Apr 29 2021

BRANFORD, CONN., April 29, 2021 — EvolveImmune Therapeutics, Inc., an emerging, privately held immunotherapy platform company, is pleased to announce that Ian Taylor, PhD has joined its board of directors.

Dr. Taylor is a veteran biopharma executive who brings exceptional biotechnology leadership to EvolveImmune’s board. He currently serves as the chief scientific officer of Arvinas, Inc. (NASDAQ:ARVN) where he manages all aspects of drug discovery research for a portfolio of novel cancer and neuroscience therapeutics. Dr. Taylor has led drug discovery and integrated development teams and programs spanning therapeutics, companion diagnostics and biomarkers.  He joined Arvinas in 2016 after nearly 10 years at Pfizer Oncology, where he held leadership roles in translational research and development, directing multiple programs in phase 1 and 2 clinical trials.  Earlier, Dr. Taylor was vice president of cancer biology at Bayer Healthcare Pharmaceuticals.

“Ian’s experience leading Arvinas’s scientific team is a perfect match with EvolveImmune’s ambitions in immunotherapy development,” said Stephen Bloch, MD, co-founder and chief executive officer of EvolveImmune.  “As EvolveImmune advances its proprietary CRISPR immune target screening platform and programs towards IND, Dr. Taylor’s guidance as a cancer biologist and a translational research leader will be invaluable. We look forward to Ian’s thoughtful insights as EvolveImmune constructs its ‘biology first’ therapeutics portfolio.”

“It is an honor to join the EvolveImmune board of directors,” Dr. Taylor said. “I am eager to work with a talented management team and board to help advance EvolveImmune’s innovative platform and drug discovery programs.”

Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in molecular biology and genetics from Harvard University. He completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).

About EvolveImmune Therapeutics, Inc.

EvolveImmune Therapeutics, Inc. is an emerging immunotherapy platform company headquartered in Branford, Connecticut.  Building upon research that originates from the Sidi Chen Laboratory at Yale University, EvolveImmune is leveraging a proprietary in vivo CRISPR-based target discovery platform to develop a broad portfolio of first-in-class therapeutics for unmet needs in oncology and immune diseases.  EvolveImmune closed a $35M series A financing in January 2020 supported by Pfizer Ventures, Solasta Ventures, Takeda Ventures, Yonjin Ventures and Elm Street Ventures.